This online, on-demand virtual symposium brings together renowned experts in HR+/HER2- breast cancer. In this educational program, these experts discuss the evolving treatment landscape for HR+/HER2- breast cancer. The program features dynamic discussions, practical insights, and updates from pivotal clinical trials that provide actionable guidance for optimizing patient care. This educational activity is an archive of a live virtual webcast held on June 8, 2026.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
100% of listed courses are free
265 of 265 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Infectious Disease
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Neurosurgery
- Nuclear Medicine
- Ophthalmology
- Pediatric Hematology-Oncology
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Surgical Oncology
- Urological Oncology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedJun 29, 2026
-
Last day to claim creditJun 30, 2027 9 months left
-
Physicians’ Education Resource Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2- Metastatic Breast Cancer-What the Latest Data Really Tell Us
-
Physicians’ Education Resource Community Oncology Connections(TM): How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2- Breast Cancer | Wisconsin Association of Hematology and Oncology
-
Physicians’ Education Resource Community Oncology Connections(TM): How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2- Breast Cancer | Empire State Hematology & Oncology Society
-
Med Learning Group Emerging Oral SERDs in Early HR+/HER2- Breast Cancer: Biomarkers, Shared Decision-Making, and Practical Management of Investigational Therapies
-
Partners for Advancing Clinical Education Fundamentals II: Advancing Therapy in HR-Positive/ HER2-Negative Metastatic Breast Cancer
-
Medscape, LLC Current and Future Oral SERD Strategies in the Management of ER+/HER2 MBC: Analyzing the Clinical Data
